Dare Bioscience Inc (NAS:DARE)

$ 3.1879 -0.0121 (-0.38%) Market Cap: 27.84 Mil Enterprise Value: 18.01 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Q3 2024 Dare Bioscience Inc Earnings Call Transcript
Nov 14, 2024

$3.57 (-7.04%)

Earnings
Q2 2024 Dare Bioscience Inc Earnings Call Transcript
Aug 12, 2024

$3.5 (+3.24%)

Earnings
Q1 2024 Dare Bioscience Inc Earnings Call Transcript
May 14, 2024

$3.78 (-0.06%)

Earnings
Q4 2023 Dare Bioscience Inc Earnings Call Transcript
Mar 28, 2024

$5.88 (-10.71%)

Earnings
Q3 2023 Dare Bioscience Inc Earnings Call Transcript
Nov 09, 2023

$3.95 (-6.93%)

Earnings
Q2 2023 Dare Bioscience Inc Earnings Call Transcript
Aug 10, 2023

$8.58 (-2.30%)

Earnings
Dare Bioscience Inc Webinar: KOL Discussion and Data Review of Exploratory Phase 2b RESPOND Study of Sildenafil Cream Transcript
Jul 11, 2023
Q1 2023 Dare Bioscience Inc Earnings Call Transcript
May 11, 2023

$12.12

Earnings
Q4 2022 Dare Bioscience Inc Earnings Call Transcript
Mar 30, 2023

$12.72 (+1.92%)

Earnings
Dare Bioscience Inc at ROTH Conference Transcript
Mar 14, 2023
Dare Bioscience Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Q3 2022 Dare Bioscience Inc Earnings Call Transcript
Nov 10, 2022

$11.03 (-2.21%)

Earnings
Q2 2022 Dare Bioscience Inc Earnings Call Transcript
Aug 09, 2022

$14.64 (-2.40%)

Earnings
Q1 2022 Dare Bioscience Inc Earnings Call Transcript
May 12, 2022

$12.36 (+9.56%)

Earnings
Q4 2021 Dare Bioscience Inc Earnings Call Transcript
Mar 31, 2022

$17.88 (+1.36%)

Earnings
Q3 2021 Dare Bioscience Inc Earnings Call Transcript
Nov 10, 2021

$20.16 (+0.60%)

Earnings
Dare Bioscience Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Dare Bioscience Inc Earnings Call Transcript
Aug 12, 2021

$20.4

Earnings
Q1 2021 Dare Bioscience Inc Earnings Call Transcript
May 13, 2021

$14.88 (-2.36%)

Earnings
Q4 2020 Dare Bioscience Inc Earnings Call Transcript
Mar 30, 2021

$19.8

Earnings
Dare Bioscience Inc at H C Wainwright BioConnect Conference (Virtual) Transcript
Jan 11, 2021
Q3 2020 Dare Bioscience Inc Earnings Call Transcript
Nov 12, 2020

$12.84 (-2.73%)

Earnings
Q2 2020 Dare Bioscience Inc Earnings Call Transcript
Aug 12, 2020

$14.16 (-0.84%)

Earnings
Dare Bioscience Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Q1 2020 Dare Bioscience Inc Earnings Call Transcript
May 14, 2020

$12.6

Earnings
Q4 2019 Dare Bioscience Inc Earnings Call Transcript
Mar 30, 2020

$10.68 (-3.26%)

Earnings
Dare Bioscience Inc 2020 Corporate Update - Call Transcript
Jan 22, 2020
Q3 2019 Dare Bioscience Inc Earnings Call Transcript
Nov 14, 2019

$9 (-4.46%)

Earnings
Q2 2019 Dare Bioscience Inc Earnings Call Transcript
Aug 14, 2019

$9.6 (+0.15%)

Earnings
Dare Bioscience Inc Annual Shareholders Meeting Transcript
Jun 13, 2019
Q1 2019 Dare Bioscience Inc Earnings Call Transcript
May 14, 2019

$11.28 (+3.33%)

Earnings
Q4 2018 Dare Bioscience Inc Earnings Call Transcript
Apr 04, 2019

$18.12 (-4.86%)

Earnings
Dare Bioscience Inc at ROTH Conference Transcript
Mar 19, 2019

Q4 2022 Dare Bioscience Inc Earnings Call Transcript

Mar 30, 2023 / 08:30PM GMT

Release Date Price: $12.72 (+1.92%)

Transcript 10-K8-K

Operator

Welcome to the conference call hosted by DarÃ© Bioscience to review the company's financial results for the year ended December 31, 2022, and to provide a general business update. This call is being recorded.

My name is Abby, and I will be your operator today. With us today are Sabrina Martucci Johnson, DarÃ©'s President and Chief Executive Officer; John Fair, DarÃ©'s Chief Commercial Officer; and Lisa Walters-Hoffert, DarÃ©'s Chief Financial Officer. Ms. Johnson, please proceed.

Sabrina Martucci Johnson;Bioscience

DarÃ;Inc. - President & CEO

© -

Thank you. Good afternoon, and welcome to our year-end December 31, 2022 financial results and business update call for DarÃ© Bioscience. Our plan today is to review our full-year results, discuss developments since our last call in November, and use the time to review our business strategy, including why we believe investment in women's health is efficient and disproportionately impactful and to highlight some important objectives and milestones anticipated in 2023.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.